Recent scientific discoveries concerning therapeutically relevant protein targets that contribute to cancer pathology have opened new possibilities in the search for effective cancer treatments. In Targets for Cancer Chemotherapy: Transcription Factors and Other Nuclear Proteins, a panel of leading basic researchers, pharmaceutical scientists, and clinical oncologists provide, in an easy-to-understand format, a detailed account of these latest research developments and spell out their implications for cancer drug discovery and clinical application. The authors identify and illuminate selected transcription factor oncoproteins and tumor suppressors, together with nuclear proteins that are central to the phenotype of the tumor cell and including recently elucidated enzymes involved with chromatin control. The emphasis is on new targets and approaches to cancer treatment derived from the cancer cell cycle, gene and chromatin control targets, and angiogenesis. Among the targets considered are E2F, Myc oncoproteins, hypoxic signaling pathways, Mdm2 and ARF, the AP-1 family of transcription factors, histone deacetylase, histone acetyl transferase, apoptin, and nuclear ß-catenin signaling.
Up-to-date and insightful, Targets for Cancer Chemotherapy: Transcription Factors and Other Nuclear Proteins shows clearly how our new understanding of critical molecular targets in cancer cells can be applied to cancer drug discovery to provide new drug discovery platforms both for future development and for new target-based medicines for cancer patients.

Klappentext

In Targets for Cancer Chemotherapy: Transcription Factors and Other Nuclear Proteins, a panel of leading basic researchers, pharmaceutical scientists, and clinical oncologists explain in detail the therapeutically-relevant protein targets that contribute to cancer pathology and spell out their implications for cancer drug discovery and clinical application. The authors identify and illuminate selected transcription factor oncoproteins and tumor suppressors, together with nuclear proteins that are central to the phenotype of the tumor cell involved in chromatin control. The emphasis is on new targets and approaches to cancer treatment derived from the cancer cell cycle, gene control targets, and angiogenesis.

Inhalt

Cancer Chemotherapy Based on E2F and the Retinoblastoma Pathway
William G. Kaelin, Jr

Myc Oncoproteins as Targets for Therapeutic Intervention in Tumorigenesis
Bernd Berwanger and Martin Eilers

The AP-1 Family of Transcription Factors: Structure, Regulation, and Functional Analysis in Mice
Marina Schorpp-Kistner, Peter Herrlich, and Peter Angel

Hypoxia-Induced Factor-1 as a Target for Anticancer Therapy
Shoumo Bhattacharya

Nuclear b-Catenin Signaling as a Target for Anticancer Drug Development
Eun Joo Chung, Paolo Bonvini, Ho Jung Oh, Len Neckers, and Jane Trepel

Histone Acetyltransferases as Potential Targets for Cancer Therapies
Stuart Thomson and Louis C. Mahadevan

Histone Deacetylases
Manfred Jung

Cyclin-Dependent Kinases and Their Small-Molecule Inhibitors in Cancer Therapy
R. Nagaraja Rao and Bharvin K. R. Patel

Mitogen-Activated Protein Kinase Cascades as Therapeutic Targets in Cancer
Antonio Chiloeches and Richard Marais

Mdm2 and ARF
Andrea Klotzbücher and Michael H. G. Kubbutat

The Breast Cancer Susceptibility Genes, BRCA1 and BRCA2
Anastasia Gabriel and Alan Ashworth

Human Papillomavirus: Targets for Therapeutic Intervention
David Pim, Miranda Thomas, and Lawrence Banks

Apoptin as an Anticancer Therapy
Mathieu H. M. Noteborn

E2F and Cancer Chemotherapy
Debabrata Banerjee and Joseph R. Bertino

Hypoxic Signaling Pathways as Targets for Anticancer Therapy
Heidi M. Sowter and Adrian L. Harris